Primary Treatment: PTC857 · Has Placebo Group · Phase 2
Experimental Group · 1 Intervention: PTC857 · Intervention Types: Drug
ActiveComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
Screening: ~3 weeks
Reporting: day 1 through week 52
Closest Location: University of South Florida - Carol and Frank Morsani Center for Advanced Healthcare · Tampa, FL
N/AFirst Recorded Clinical Trial
1 TrialsResearching Amyotrophic Lateral Sclerosis
0 CompletedClinical Trials
Age 18+ · All Participants · 8 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:
You have a symptom onset of at least 7 and up to 18 months before the initial screening visit.
You have a total ALSFRS-R score of at least 34 at the start of the Screening Period.
You have no significant respiratory compromise as evidenced by slow vital capacity ≥60% or a respiratory rate ≥30/min.
Female participants must have a negative breast cancer imaging screening status (not considered clinically abnormal and/or requiring further evaluation/treatment) within 6 months prior to the Screening Visit, or during the Screening Period.
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.